- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.08. | Polyrizon regains compliance with Nasdaq listing requirements | 2 | Investing.com | ||
| 14.08. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.08. | Polyrizon Ltd.: Polyrizon Regains Compliance with Nasdaq Listing Requirements | 261 | GlobeNewswire (Europe) | Ra'anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| 31.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.07. | Polyrizon Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 22.07. | Polyrizon Stock Jumps 53% On Positive Preclinical Results For Allergy Blocker | 1 | RTTNews | ||
| 22.07. | Polyrizon-Aktie steigt nach positiven Studiendaten für Allergie-Nasenspray stark an | 4 | Investing.com Deutsch | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 22.07. | Polyrizon stock soars after promising nasal allergy blocker test results | 5 | Investing.com | ||
| 22.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.07. | Polyrizon meldet vielversprechende Ergebnisse für nasalen Allergenblocker | 2 | Investing.com Deutsch | ||
| 22.07. | Polyrizon's nasal allergy blocker shows promising deposition results | 1 | Investing.com | ||
| 22.07. | Polyrizon Ltd.: Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study | 130 | GlobeNewswire (Europe) | Ra'anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| 16.07. | Polyrizon Stock Slides After Hours After 52% Surge On Tuesday: Why It Moved | 1 | Benzinga.com | ||
| 15.07. | Polyrizon Shares Jump Over 38% After Securing Nasdaq Listing Extension | 2 | RTTNews | ||
| 15.07. | Polyrizon retains Nasdaq listing following hearings panel | 2 | Seeking Alpha | ||
| 15.07. | Polyrizon secures continued Nasdaq listing after panel hearing | 2 | Investing.com | ||
| 15.07. | Polyrizon sichert sich nach Anhörung Verbleib an der NASDAQ | 2 | Investing.com Deutsch | ||
| 15.07. | Polyrizon Ltd.: Polyrizon Retains Nasdaq Listing Following Hearings Panel | 266 | GlobeNewswire (Europe) | Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 15.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.06. | Polyrizon-Direktor Omer Srugo tritt zurück; Vorstand bestätigt unabhängige Mitglieder | 1 | Investing.com Deutsch |
1 2 3 4 Weiter >>
70 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,495 | -1,50 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen nach einer Investorenveranstaltung auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Das Interesse der Teilnehmer... ► Artikel lesen | |
| NOVAVAX | 6,409 | -0,47 % | Milliarden-Verlustgefahr: Nach zweistelligem Absturz: Warum Novavax-Investoren weiter zittern müssen | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenNovavax steht unter massivem Druck: Ein Analysten-Downgrade, neue Milliarden-Schulden und Zweifel an der Impfstoff-Zukunft haben die Aktie... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,880 | +7,43 % | Inovio says FDA agrees with rolling BLA submission for rare disease asset | ||
| COSCIENS BIOPHARMA | 2,400 | -11,11 % | COSCIENS Biopharma Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| XOMA ROYALTY | 29,400 | 0,00 % | Mural Oncology plc: Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share | WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company ("Mural"), and XOMA Royalty Corporation... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| PHIO PHARMACEUTICALS | 2,005 | -0,74 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 1,115 | 0,00 % | ORAGENICS INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| LADRX | - | - | LadRx Corp - 8-K, Current Report | ||
| VIVUS | - | - | Vivus' Qsymia gains market approval in UAE for obesity treatment | ||
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,108 | -1,82 % | $700M BNB-Transaktion kann Windtree nicht vor dem Nasdaq-Delisting retten | ||
| SERES THERAPEUTICS | 16,100 | -3,36 % | XFRA 1S90: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
POLYRIZON LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,45 % bei einem Aktienkurs von 1,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.